Novonesis A/S (NVZMY) and Its Competitors Critical Survey

Novonesis A/S (OTC:NVZMY) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Novonesis A/S to related companies based on the strength of its dividends, profitability, analyst recommendations, risk, earnings, institutional ownership and valuation.

Volatility and Risk

Novonesis A/S has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Novonesis A/S’s competitors have a beta of 1.03, meaning that their average share price is 3% more volatile than the S&P 500.

Profitability

This table compares Novonesis A/S and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novonesis A/S	N/A	N/A	N/A
Novonesis A/S Competitors	-2,185.76%	-161.46%	-40.62%

Analyst Recommendations

This is a breakdown of recent ratings for Novonesis A/S and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novonesis A/S	1	0	0	0	1.00
Novonesis A/S Competitors	1871	5281	13648	288	2.59

As a group, “Biological products, except diagnostic” companies have a potential upside of 83.23%. Given Novonesis A/S’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Novonesis A/S has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Novonesis A/S and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Novonesis A/S	$2.60 billion	$439.08 million	35.47
Novonesis A/S Competitors	$601.82 million	-$69.39 million	-1.39

Novonesis A/S has higher revenue and earnings than its competitors. Novonesis A/S is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

0.0% of Novonesis A/S shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dividends

Novonesis A/S pays an annual dividend of $0.35 per share and has a dividend yield of 0.6%. Novonesis A/S pays out 22.2% of its earnings in the form of a dividend. As a group, “Biological products, except diagnostic” companies pay a dividend yield of 2.3% and pay out 112.8% of their earnings in the form of a dividend.

Summary

Novonesis A/S competitors beat Novonesis A/S on 8 of the 15 factors compared.

About Novonesis A/S

Novonesis A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novonesis A/S was founded in 1925 and is based in Bagsvaerd, Denmark.